Moderna Inc. confirmed on Monday that its coronavirus vaccine candidate is 94.1% efficient in stopping the virus and that it is estimated to direct regulators in the United States and Europe for an emergency use authorization (EUA) later today.
Chief Executive Stephane Bancel stated that “this positive primary analysis confirms the ability of our vaccine to prevent COVID-19 disease with 94.1% efficacy and importantly, the ability to prevent severe COVID-19 disease. We believe that our vaccine will provide a new and powerful tool that may change the course of this pandemic and help prevent severe disease, hospitalizations and death.”
The vaccine investigation conducted by the United States Food and Drug Administration (FDA) should continue a couple of weeks, Moderna estimated, remarking that an advisory board meeting will likely take place on December 17.
What's happening in Tunisia?
Subscribe to our Youtube channel for updates.
